Exogenous administration of recombinant TRAIL or agonistic TRAIL-R antibodies can induce apoptosis in tumor cells and immunosuppressive cells (such as TAMs and Tregs), leading to an increase in cytotoxic T lymphocyte (CTL) numbers and enhanced phagocytic capabilities of neutrophils, monocytes, and macrophages (151). The gene discussed is TNFSF10; the disease is neoplasm.